Jump to navigation Jump to content

Edinburgh's Health Innovation District

The Vision

Edinburgh BioQuarter is undergoing a transformation. Our vision is to rapidly grow the site into a vibrant mixed use neighbourhood of Edinburgh, centred around a world-leading community of healthcare innovators. By developing at scale and at pace together with a private sector partner we will accelerate solutions to global health challenges. BioQuarter will support a community of more than 20,000 as part of Edinburgh’s Health Innovation District.


Watch our film

The Opportunity

Where people live, learn, work, play, relax and discover

BioQuarter Strategy Board intends to seek a joint venture partner to be part of an ambitious vision to create a new vibrant mixed-use neighbourhood in Edinburgh. With a Gross Development Value estimated at over £750m, there is an opportunity to develop in phases the remaining 67 acres of underdeveloped land (estimated at circa 4m sq ft. of development). Interested parties will be invited to take part in a OJEU Competitive Dialogue procurement process, which will include, but is not limited to, the following services:

  • Funding
  • Commercialisation and knowledge exchange management
  • Construction
  • Development management
  • Hard and soft facilities management


through the
east region
city deal

Invest in Our Companies

Scotland’s top life sciences companies at BioQuarter

We view the 25+ companies who choose to call BioQuarter home as very special and we want to support them to grow and succeed. We are proud that these multi award-winning life sciences companies and entrepreneurs have chosen to come here. We welcome and support investment into our tenant companies, and with two recent acquisitions in excess of £200m+ there are many opportunities amongst our growing cluster.

  • Roslin Cells based at BioQuarter has created over 80 new jobs and given rise to two further spin-off companies (Roslin CT and CENSO)
  • IoMET was a new start-up based at BioQuarter and was acquired by Merck for >£100s millions in 2016
  • Janssen Pharmaceuticals has invested over £6m to establish the Centre for Dementia Prevention at BioQuarter, with a commitment to recruit 100s of patients for dementia research
See the Companies at BioQuarter


new life science
companies raising £10m in
in the last
five years

Property and Commercial Agents

Edinburgh BioQuarter is working with consultant partners, Savills and CAM-SCI, in regards to property and commercial developments. For more information on property, viewings and development opportunities please contact our agents.

Commercialisation and Clinical Trials

Latest Case Studies


Fios Genomics

Specialists in bioinformatics data analysis, Fios Genomics works with global pharmaceutical companies, contract research organisations and academic institutions from its BioQuarter base.


Centre for Dementia Prevention

Based at BioQuarter since 2016, the University of Edinburgh’s Centre for Dementia Prevention is leading a major worldwide study into the condition.



Hugely innovative in shortening the distance from bench to bedside, the QMRI-based Proteus project’s work is revolutionising the ways lung diseases are diagnosed and managed.


Centre for Cardiovascular Science

The Centre for Cardiovascular Science (CVS) is engaged in world-leading research into cardiovascular diseases. Co-located with the Royal Infirmary of Edinburgh and the University of Edinburgh’s Medical School, the CVS relies on collaboration to both drive discoveries and deliver new solutions.



Founded in 2012 by CEO Adam Christie and CTO Bruce Vernon, CALCIVIS has recently overseen the UK launch of its revolutionary dental imaging technology.


Aquila BioMedical

Beginning life as a University of Edinburgh start-up, Aquila BioMedical’s expertise in immunology, immuno-oncology and specialist histology supports a range of clients to discover their best route to clinic.